Products
Biosimilars
End-to-End Expertise for Biosimilar Development
Provis offers comprehensive biosimilar development services spanning the complete product lifecycle from early discovery through commercial manufacturing. Our capabilities in Microbial (E. coli) and Mammalian (CHO) expression systems enable us to support diverse therapeutic proteins across multiple complexity levels and therapeutic areas.
Proven Biosimilar Development Expertise
Our team brings demonstrated experience in successfully developing and commercializing 20+ Complex biosimilars (proteins and monoclonal antibodies) with proven capabilities in:
- Accelerated development timelines
- Global regulatory approvals
- International technology licensing and partnership
- Complex biologics from development to commercial launch
Capabilities
Our Integrated R&D Platform
As a fully integrated biologics development partner, we support programs from target validation to regulatory filing, with a focus on quality, scalability and GMP readiness.
Our Service Capabilities Include:
Late Discovery & Feasibility Studies
Target validation, construct design and expression system selection.
Cell Line Development
Stable, high-yielding clones for both microbial and mammalian platforms.
Process Development
Upstream and downstream optimization for commercial-scale manufacturing.
Analytical Development
Comprehensive characterization, comparability and biosimilarity assessment.
Non-GMP and cGMP Manufacturing
Scalable production to support preclinical through clinical supply and IND filing.
Our Core Expertise
Our expertise covers mammalian and microbial systems, with optimized bacterial fermentation (E. coli) and mammalian cell cultures, primarily CHO (Chinese Hamster Ovary) cells.
Mammalian Expression (CHO)
Our mammalian platform supports complex, glycosylated biologics, including monoclonal antibodies and Fc-fusion proteins.
- CHO cell line development and optimization
- Advanced bioprocessing for glycosylation control
- Post-translational modification profiling
- Biosimilarity and comparability frameworks
Microbial Expression (E. coli)
Our microbial platform is optimized for non-glycosylated proteins, including growth factors, cytokines, enzymes.
- High-density bacterial fermentation
- Cost-effective production models
- Rapid development timelines
- Established purification and refolding strategies
Focus Areas
Therapeutic Focus Areas
Provis focuses on biosimilar development across multiple high-impact therapeutic areas:
Oncology
Monoclonal antibodies and targeted biologics
Metabolic Disorders
Hormone therapies and enzyme replacements
Rheumatoid Arthritis & Autoimmune Diseases
Anti-inflammatory biologics
Bone Health (Osteoporosis)
Bone metabolism regulators
Business Model
In-House Development +
Strategic Partnerships
This model enables faster time-to-market, reduced development costs and shared risk while leveraging our technical expertise and your commercial capabilities.
Provis-Led Development
Economical production processes, extensive analytical characterization and regulatory strategy development completed in-house.
Partner-Led Commercialization
Collaboration with biopharmaceutical companies for clinical development, regulatory approval and market access.
Let's Advance Global Biosimilar Access Together
Partner with Provis to accelerate your biosimilar portfolio with proven technologies, comprehensive development support and a shared commitment to expanding patient access to life-changing biologics.